NCT03257046View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ITI-214 in Parkinson's Disease

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 28, 2017

Primary Completion Date

September 6, 2018

Study Completion Date

September 28, 2018

Conditions
Parkinson Disease
Interventions
DRUG

ITI-214

Oral

OTHER

Placebo

Oral

Trial Locations (2)

27708

Duke Early Phase Research Unit, Durham

30331

Atlanta Center for Medical Research, Atlanta

Sponsors
All Listed Sponsors
lead

Intra-Cellular Therapies, Inc.

INDUSTRY